发布求助
文献互助 智能选刊 最新文献

Lung Cancer - Modern Multidisciplinary Management最新文献

筛选
英文 中文
Bone Metastases in Lung Cancer 肺癌的骨转移
Lung Cancer - Modern Multidisciplinary Management Pub Date : 2021-03-15 DOI: 10.5772/INTECHOPEN.96902
Ana C. Belzarena
{"title":"Bone Metastases in Lung Cancer","authors":"Ana C. Belzarena","doi":"10.5772/INTECHOPEN.96902","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.96902","url":null,"abstract":"Lung cancer patients frequently present with to bone metastases. Such lesions are responsible for increased morbidity, low quality of life, and increased costs to patients and the health care system. Pain is the most common symptom; however, these lesions also present as skeletal related events (SRE) which include pathological fractures, hypercalcemia, spinal cord and nerve compressions and cause the need for surgery and/or radiotherapy. Even though bone metastases are associated with poor prognosis, current treatment multimodalities continue to improve survival. Awareness and effective treatment of these lesions is paramount to maintain a good quality of life and function in lung cancer patients.","PeriodicalId":113892,"journal":{"name":"Lung Cancer - Modern Multidisciplinary Management","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131087030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer 肺癌循环肿瘤生物标志物液体活检分析
Lung Cancer - Modern Multidisciplinary Management Pub Date : 2020-12-21 DOI: 10.5772/intechopen.95422
P. Lin
{"title":"Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer","authors":"P. Lin","doi":"10.5772/intechopen.95422","DOIUrl":"https://doi.org/10.5772/intechopen.95422","url":null,"abstract":"Risk stratification, prognostication and longitudinal monitoring of therapeutic efficacy in lung cancer patients remains highly challenging. It is imperative to establish robust surrogate biomarkers for identifying eligible patients, predicting and effectively monitoring clinical response as well as timely detecting emerging resistance to therapeutic regimens. Circulating tumor biomarkers, analyzed by liquid biopsy, are primarily composed of nucleic acid-based circulating tumor DNA (ctDNA) and an aneuploid cell-based category of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs). Unlike ctDNA, cancer cells are the origin of all categories of various tumor biomarkers. Involvement of aneuploid CTCs and CTECs in tumorigenesis, neoangiogenesis, tumor progression, cancer metastasis and post-therapeutic recurrence has been substantially investigated. Both CTCs and CTECs possessing an active interplay and crosstalk constitute a unique category of cellular circulating tumor biomarkers. These cells concurrently harbor the intact cancer-related genetic signatures and full tumor marker expression profiles in sync with disease progression and therapeutic process. Recent progress in clinical implementation of non-invasive liquid biopsy has made it feasible to frequently carry out ctDNA analysis and unbiased detection of a full spectrum of non-hematologic circulating rare cells including CTCs and CTECs in lung cancer patients, regardless of variation in heterogeneous cell size and cancer cell surface anchor protein expression. In situ phenotypic and karyotypic comprehensive characterization of aneuploid CTCs and CTECs, in combination with single cell-based genotyping and improved ctDNA analyses, will facilitate and benefit multidisciplinary management of lung cancer.","PeriodicalId":113892,"journal":{"name":"Lung Cancer - Modern Multidisciplinary Management","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122113382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer 少转移性非小细胞肺癌治疗的挑战
Lung Cancer - Modern Multidisciplinary Management Pub Date : 2020-12-01 DOI: 10.5772/intechopen.94567
M. Vrankar
{"title":"Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer","authors":"M. Vrankar","doi":"10.5772/intechopen.94567","DOIUrl":"https://doi.org/10.5772/intechopen.94567","url":null,"abstract":"Since 1995, when the concept of oligometastatic non-small cell lung cancer was first described, no high-level evidence has been introduced for management of those patients subset. Data from retrospective reports and analysis and from every-day clinical practice revealed that some of the non-small cell lung cancer patients with a few metastases could benefit significantly with local radical treatment approach of primary and metastatic lesions. Recent advances in modern local treatment approaches with minimally invasive surgery and stereotactic radiotherapy, as well as introduction of immunotherapy, open new field of interest for personalized treatment of limited metastatic non-small cell lung cancer. In this report, we are summarizing limited data of case reports, retrospective studies and few randomized studies of patients with oligometastatic non-small cell lung cancer and discuss challenges of treatment in the era of molecular targeted therapy and immunotherapy.","PeriodicalId":113892,"journal":{"name":"Lung Cancer - Modern Multidisciplinary Management","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117006995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes 肺癌精准医学:诊断和治疗目的的挑战和机遇
Lung Cancer - Modern Multidisciplinary Management Pub Date : 2020-11-17 DOI: 10.5772/intechopen.94840
B. Aramini, V. Masciale, F. Banchelli, R. D'amico, M. Dominici, K. Haider
{"title":"Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes","authors":"B. Aramini, V. Masciale, F. Banchelli, R. D'amico, M. Dominici, K. Haider","doi":"10.5772/intechopen.94840","DOIUrl":"https://doi.org/10.5772/intechopen.94840","url":null,"abstract":"Lung cancer is one of the leading causes of cancer death among both men and women, making up almost 25% of all cancer deaths. Precision medicine shows promise for improving many aspects of health and healthcare, including tests, drugs, and other technologies that support innovation, with the possibility of new partnerships with scientists in a wide range of specialties. Non–small-cell lung cancer (NSCLC) has become a prominent example of the success of precision medicine in treating solid tumor malignancies. The first step in this process involves new blood-based diagnostics, which can now noninvasively provide clinically useful information. However, the identification of novel biomarkers that could be used in early diagnosis is urgently needed, especially for guiding initial therapy and predicting relapse or drug resistance following the administration of novel targeted therapies.","PeriodicalId":113892,"journal":{"name":"Lung Cancer - Modern Multidisciplinary Management","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131234801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Radiotherapy: An Alternative to Surgery 放射治疗:手术的另一种选择
Lung Cancer - Modern Multidisciplinary Management Pub Date : 2020-10-30 DOI: 10.5772/intechopen.94486
Van Houtte Paul, Charlier Florian, M. Luigi, V. Dirk
{"title":"Radiotherapy: An Alternative to Surgery","authors":"Van Houtte Paul, Charlier Florian, M. Luigi, V. Dirk","doi":"10.5772/intechopen.94486","DOIUrl":"https://doi.org/10.5772/intechopen.94486","url":null,"abstract":"Many major technical developments have occurred during the last decades in radiotherapy: our efficacy has improved with less toxicity. Nowadays, it allows us to challenge the role of surgery as a local modality for lung cancer both for early, advanced and even metastatic disease. In the present paper, we will mainly discuss the role of SBRT for stage I lung cancer, the place of conventional radiotherapy for stage III and we will review the current treatment of small cell lung cancer from a radiation oncologist perspective.","PeriodicalId":113892,"journal":{"name":"Lung Cancer - Modern Multidisciplinary Management","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115862935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信